Tenpoint Therapeutics Appoints Melissa Epperly as Chief Financial Officer to Drive Financial Strategy for BRIMOCHOL PF Launch

Tenpoint Therapeutics has appointed Melissa Epperly as its new Chief Financial Officer. Epperly has over 20 years of financial leadership experience in the biopharmaceutical industry, having served as CFO for both public and private companies. She will oversee Tenpoint's financial strategy, capital markets activities, and operational finance functions as the company prepares for the potential US launch of its lead candidate, BRIMOCHOL™ PF, for presbyopia treatment. Epperly's experience and financial firepower will be a significant asset to Tenpoint as it grows into a commercial-stage company.

Title: Tenpoint Therapeutics Appoints Melissa Epperly as Chief Financial Officer

Tenpoint Therapeutics, Ltd., a global, clinical-stage biotechnology company focused on developing treatments to rejuvenate vision in the aging eye, has appointed Melissa Epperly as its new Chief Financial Officer (CFO). Epperly brings over two decades of financial leadership experience in the biopharmaceutical industry, having served as CFO for both public and private companies. She will oversee Tenpoint’s financial strategy, capital markets activities, and operational finance functions as the company prepares for the potential U.S. launch of BRIMOCHOL™ PF, its lead candidate for the treatment of presbyopia.

Epperly’s extensive background includes roles at Zentalis Pharmaceuticals, where she led the company through a successful IPO and subsequent financings, raising over $1.25 billion. Prior to that, she held CFO positions at PsiOxus Therapeutics and R-Pharm US, as well as strategic and financial roles at Anchorage Capital, Goldman Sachs, Bain & Company, and Morgan Stanley. Her current board memberships include Roivant Sciences and Nautilus Biotechnology, both of which are listed on Nasdaq. Epperly holds an MBA from Harvard Business School and a BA in Biochemistry and Economics from the University of Virginia, where she graduated Phi Beta Kappa.

Henric Bjarke, Chief Executive Officer of Tenpoint Therapeutics, commented, "Melissa brings the vision, energy, and financial firepower we need as we prepare for the launch of BRIMOCHOL™ PF into global markets. Her deep capital markets experience and strong operational command will be a tremendous asset as Tenpoint grows into a commercial-stage company."

Epperly stated, "It’s an honor to join Tenpoint at such a defining moment. With breakthrough science, bold goals, and a clear vision for impact, this team is poised to do something extraordinary. I’m eager to help shape what’s ahead as we advance BRIMOCHOL™ PF and build toward lasting growth."

Tenpoint Therapeutics is backed by a robust investment portfolio that includes AdBio Partners, AlbionVC, British Business Bank, Eight Roads, EQT Life Sciences, F-Prime Capital, Hillhouse Capital Management, Qiming Venture Partners USA, Sofinnova Partners, and Wille AG. The company’s pipeline includes paradigm-shifting treatments for ophthalmic indications with high market potential, including presbyopia, cataracts, and geographic atrophy.

The appointment of Epperly is timely as the market for myopia and presbyopia treatment is projected to witness significant growth, driven by increasing prevalence and advanced treatment options [2]. The market is expected to be valued at US$ 28.62 billion in 2025, with a compound annual growth rate (CAGR) of 8.3% over the forecast period 2025 to 2032 [2].

References
[1] https://www.businesswire.com/news/home/20250602667163/en/Tenpoint-Therapeutics-Ltd.-Appoints-Melissa-Epperly-as-Chief-Financial-Officer
[2] https://www.openpr.com/news/4042831/myopia-and-presbyopia-treatment-market-projected-to-witness